in

Unity HA Adds Jon J. Snyder as CEO, Announces Name Change to Realeve™

Effingham, Illinois, August 18, 2021 (Business Wire) — Unity HA today announced the addition of Jon J. Snyder as Chief Executive Officer. Snyder holds nearly 30 years of global management experience in biomedical and healthcare sales, marketing, and operations with significant experience in bringing new products into the marketplace. Snyder is also the founding CEO and an Executive Advisor of Neuros Medical, a Cleveland, Ohio based medical device company, which he led through the past several years of development, raising $35 million in venture capital and strategic partner investment. The company also announced the change of their name from Unity HA, to Realeve, to support the commercialization process for their Pulsante® SPG Microstimulator System for cluster headache.

“We are extremely pleased to add a proven, medical device executive with strong neuromodulation and chronic pain therapy development experience in Jon Snyder to lead Realeve going forward.”

Snyder’s background covers business development, product development, market management, sales management, venture capital investment, and fundraising at start-up and Fortune 500 companies including Cyberonics, Cardinal Health, Imalux, and STERIS.

Unity HA Founder, Dr. Peter Bonutti said, “We are extremely pleased to add a proven, medical device executive with strong neuromodulation and chronic pain therapy development experience in Jon Snyder to lead Realeve going forward.”

Snyder added, “It is an honor to join the Realeve team and move this impactful therapy closer to the market. The Unity HA team has done an outstanding job with the Pulsante SPG Microstimulator System for the treatment of acute headache pain associated with chronic cluster headaches. We look forward to advancing this therapy to obtain the regulatory approvals to launch the therapy.”

Source: https://www.businesswire.com/news/home/20210818005115/en/Unity-HA-Adds-Jon-J.-Snyder-as-CEO-Announces-Name-Change-to-Realeve%E2%84%A2

Headlines

Vigil Neuroscience Completes $90 million Series B Financing

Headlines

Immunitas Therapeutics Completes $58 Million Series B Financing